Scientific Technology and R&D

Technology Platform

We are one of the few biotechnology companies globally adopting a systematic therapeutic approach to harness both the innate and adaptive immune systems, unleashing their synergistic potential to address the limitations of T-cell-based immunotherapies. Currently approved immuno-oncology therapies promote immune responses primarily through approaches that target T-cell immune checkpoints, exemplified by PD-1/PD-L1, CTLA-4 and LAG3.

CD47-based drug candidates
CD47-based drug candidates

IMM01

IMM0306

IMM2902

IMM2520

IMM4701

Innate immune checkpoint CD24
Innate immune checkpoint CD24

IMM47

IMM4701

IMM2547

CD47-based bispecific molecules
CD47-based bispecific molecules

IMM0306

IMM2902

IMM2520

Adaptive immunity-based drug candidates
Adaptive immunity-based drug candidates

IMM2510

IMM27M

IMM40H

0.085668s